Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Northwest Biotherapeutics (NWBO) over the last 10 years, with Q3 2025 value amounting to $10.3 million.

  • Northwest Biotherapeutics' Non-cash Items rose 4020.17% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.6 million, marking a year-over-year increase of 8381.87%. This contributed to the annual value of $16.8 million for FY2024, which is 3240.1% up from last year.
  • According to the latest figures from Q3 2025, Northwest Biotherapeutics' Non-cash Items is $10.3 million, which was up 4020.17% from $3.8 million recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Non-cash Items peaked at $114.6 million during Q3 2022, and registered a low of -$143.9 million during Q4 2021.
  • Its 5-year average for Non-cash Items is -$1.6 million, with a median of $2.6 million in 2024.
  • Its Non-cash Items has fluctuated over the past 5 years, first plummeted by 18380.5% in 2023, then soared by 59287.05% in 2024.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Non-cash Items stood at -$143.9 million in 2021, then surged by 111.15% to $16.0 million in 2022, then plummeted by 87.29% to $2.0 million in 2023, then surged by 192.15% to $6.0 million in 2024, then skyrocketed by 72.79% to $10.3 million in 2025.
  • Its Non-cash Items was $10.3 million in Q3 2025, compared to $3.8 million in Q2 2025 and $3.5 million in Q1 2025.